

amended sheet

WO00/27425

(NEW) CLAIMS:

- Sub
A
09531680-010902
1. A pharmaceutical preparation for the treatment of blood coagulation disorders containing at least one pro-protein of blood coagulation, selected from the group of factor VIII, von Willebrand factor (vWF) or factor V, and, in addition, a coagulation physiologically inert receptor binding competitor selected from the group of RAP, a RAP mutant, a RAP analogue and the combination of tissue type plasminogen activator (tPA) and aprotinin.
 2. A preparation according to claim 1, characterized in that said pro-protein is derived from a biological material selected from the group of human plasma, a plasma fraction and a cell culture supernatant.
 3. A preparation according to claim 1 or 2, characterized in that it is provided as a set containing
 - a) said pro-protein of blood coagulation and
 - b) said receptor binding competitor.
 4. A preparation according to any one of claims 1 to 3, characterized in that said pro-protein of blood coagulation is factor VIII and said receptor binding competitor is a mixture of aprotinin and tPA.
 5. A preparation according to any one of claims 1 to 3, characterized in that said pro-protein of blood coagulation is vWF and said receptor binding competitor is a mixture of aprotinin and tPA.
 6. A combination preparation containing aprotinin and tPA for medical use.
 7. The use of a preparation according to any one of claims 1 to 5 for the preparation of a means to treat a patient suffering from phenotypic coagulation factor deficiency.
 8. The use according to claim 7, characterized in that said patient is vWF deficient.
 9. The use of a preparation according to any one of claims 1 to 5 for the preparation of a means to extend the biological *in vivo* half-life of said protein.
 10. The use of a preparation according to claim 9 containing aprotinin and tPA.
- Sub
A2
- Sub
A3

amended sheet

WO00/27425

Sub
Q3
cont
11. The use according to ~~claim 9~~ characterized in that said protein is blood coagulation factor VIII.

12. The use of a pharmaceutical preparation containing a coagulation physiologically inert receptor binding competitor selected from the group of RAP, a RAP mutant, a RAP analogue and the combination of tissue type plasminogen activator (tPA) and aprotinin to extend the biological half-life of a protein selected from the group of factor VIII, factor V and vWF.

09071600-010902
200610-0891850